Pricking the skin with insulin syringes could be a thing of the past for more than 145,000 Australians living with type 1 diabetes due to the approval of a breakthrough treatment.
Heralded as the most important innovation since insulin was discovered more than 100 years ago, Tzield (teplizumab) is expected to delay the onset of the autoimmune disease for patients as young as eight.
